Company / Capital Expenditures
MAXCYTE, INC. Capital Expenditures History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$1.8M
FY2025
5-year range
$1.8M / $18.5M
FY2021-FY2025
Trend
-52.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $18M to $2M over the past 2 years.
Based on SEC 10-K filings.
$2M in FY2025 with a 3-year CAGR of -54.3%.
Declined from $18M to $2M over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -54.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -54.3%, indicating a declining trend.
- In FY2025, capital expenditures decreased 52.2% year-over-year.
- Peak capital expenditures was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.96 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.8M | -52.2% |
| FY2024 | $3.7M | -80.0% |
| FY2023 | $18.5M | +0.0% |
| FY2022 | $18.5M | +381.9% |
| FY2021 | $3.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026